ZNF276 (zinc finger protein 276) is a transcriptional regulatory protein located on chromosome 16.4 that contains zinc finger domains enabling sequence-specific double-stranded DNA binding 1. The protein functions as a DNA-binding transcription activator, likely regulating RNA polymerase II-mediated transcription through binding to cis-regulatory regions in the nucleus [GO Annotations]. ZNF276 exhibits heterogeneous expression patterns, with differential transcription factor activity identified in neonatal neutrophil subpopulations 2. Clinically, ZNF276 has relevance to multiple disease contexts. Genomic variants in ZNF276 associate with skin autofluorescence—a biomarker reflecting advanced glycation endproduct accumulation linked to type 2 diabetes and cardiovascular disease risk 1. An intronic splice-site variant (c.1350-2A>G) in ZNF276 was identified in a Han Chinese family with autosomal recessive non-syndromic hearing loss 3. Additionally, ZNF276 was incorporated into a prognostic risk model for predicting castrate-resistant prostate cancer outcomes in patients receiving androgen deprivation therapy, suggesting involvement in treatment resistance mechanisms 4. Loss of heterozygosity at the ZNF276 chr16 locus (16q23.4) occurs frequently in breast tumors, and amino acid variants show possible associations with tumorigenesis 5. These findings indicate ZNF276 functions in transcriptional regulation with potential tumor suppressive properties and disease associations spanning metabolic, auditory, and oncologic domains.